🔗 Visit the ClinicalTrials.gov page for NCT01011530
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Pro-senescence therapy for cancer treatment. | Nat Rev Cancer | 2011 | 2.75 |
| 2 | Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. | Antioxid Redox Signal | 2014 | 1.06 |
| 3 | MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis. | Br J Pharmacol | 2015 | 0.82 |
| 4 | The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. | Cell Death Discov | 2015 | 0.81 |
| 5 | Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. | EBioMedicine | 2016 | 0.76 |
| 6 | A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. | Invest New Drugs | 2016 | 0.76 |